Alumis
Los Angeles, California, United States · Biotechnology, Healthcare, Health Care · 200 employees
A California-based biotech company specializing in developing oral therapies for immune dysfunction and autoimmune indications, with a focus on TYK2 inhibition.
Funding history
- Venture - Series Unknown — $40.0M — Jul 2024
- Venture - Series Unknown — $129.5M — Mar 2024
- Series C — $259.0M — Mar 2024
- Venture - Series Unknown — $60.0M — Mar 2021
- Venture - Series Unknown — $10.5M — Feb 2021
Recent signals
- Jan 02, 2026: Alumis Inc. Issues Claim for Indemnification Due to Breach by Climb Bio, Inc.
- Jan 02, 2026: SEC 8-K (8.01): On January 2, 2026, Alumis Inc. and its subsidiary Acelyrin, Inc. issued a Notice of Material Breach and Notification of Claim for Indemnification against Climb Bio, Inc. due to Climb Bio's refusal to pay a $3,000,000 Development Milestone payment that was due on January 1, 2026, as stipulated in the Asset Purchase Agreement dated January 11, 2024. This breach relates to a total potential obligation of $157.5 million that Climb Bio had agreed to pay to Acelyrin, contingent on achieving various milestones. The company is now seeking to enforce these financial obligations, which may impact their future collaborations and revenue projections.
- Jul 24, 2024: Raised $40.0M in Venture - Series Unknown
- Mar 11, 2024: Raised $129.5M in Venture - Series Unknown
- Mar 07, 2024: Alumis Appoints New Executives
- Mar 06, 2024: Raised $259.0M in Series C
- Mar 19, 2021: Raised $60.0M in Venture - Series Unknown
- Feb 25, 2021: Raised $10.5M in Venture - Series Unknown
See plans & pricing → Track Alumis’s funding, hiring, and signals — with verified contacts — on Fundz.